STRATEC SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally.
Reasonable growth potential average dividend payer.
Share Price & News
How has Stratec's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SBS has not had significant price volatility in the past 3 months.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: SBS underperformed the German Medical Equipment industry which returned 25% over the past year.
Return vs Market: SBS exceeded the German Market which returned 13.7% over the past year.
Price Volatility Vs. Market
How volatile is Stratec's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StThe Stratec (ETR:SBS) Share Price Has Gained 65% And Shareholders Are Hoping For More
3 weeks ago | Simply Wall StShould You Be Concerned About Stratec SE's (ETR:SBS) ROE?
1 month ago | Simply Wall StStratec (ETR:SBS) Seems To Use Debt Quite Sensibly
Is Stratec undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: SBS (€68.6) is trading above our estimate of fair value (€51.37)
Significantly Below Fair Value: SBS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SBS is poor value based on its PE Ratio (60.7x) compared to the Medical Equipment industry average (42.1x).
PE vs Market: SBS is poor value based on its PE Ratio (60.7x) compared to the German market (20.9x).
Price to Earnings Growth Ratio
PEG Ratio: SBS is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: SBS is good value based on its PB Ratio (5.5x) compared to the DE Medical Equipment industry average (5.9x).
How is Stratec forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SBS's forecast earnings growth (32.3% per year) is above the savings rate (-0.4%).
Earnings vs Market: SBS's earnings (32.3% per year) are forecast to grow faster than the German market (13.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SBS's revenue (9.9% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: SBS's revenue (9.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SBS's Return on Equity is forecast to be low in 3 years time (18%).
How has Stratec performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SBS has high quality earnings.
Growing Profit Margin: SBS's current net profit margins (6.3%) are lower than last year (8.5%).
Past Earnings Growth Analysis
Earnings Trend: SBS's earnings have declined by -5.8% per year over the past 5 years.
Accelerating Growth: SBS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SBS had negative earnings growth (-17.6%) over the past year, making it difficult to compare to the Medical Equipment industry average (17%).
Return on Equity
High ROE: SBS's Return on Equity (9%) is considered low.
Return on Assets
Return on Capital Employed
How is Stratec's financial position?
Financial Position Analysis
Short Term Liabilities: SBS's short term assets (€130.0M) exceed its short term liabilities (€44.4M).
Long Term Liabilities: SBS's short term assets (€130.0M) exceed its long term liabilities (€104.9M).
Debt to Equity History and Analysis
Debt Level: SBS's debt to equity ratio (54%) is considered high.
Reducing Debt: SBS's debt to equity ratio has increased from 6.6% to 54% over the past 5 years.
Debt Coverage: SBS's debt is not well covered by operating cash flow (9.4%).
Interest Coverage: SBS's interest payments on its debt are well covered by EBIT (18.7x coverage).
Inventory Level: SBS has a high level of physical assets or inventory.
Debt Coverage by Assets: SBS's debt is covered by short term assets (assets are 1.6x debt).
What is Stratec's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: SBS's dividend (1.2%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.31%).
High Dividend: SBS's dividend (1.2%) is low compared to the top 25% of dividend payers in the German market (3.65%).
Stability and Growth of Payments
Stable Dividend: SBS's dividends per share have been stable in the past 10 years.
Growing Dividend: SBS's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (72.6%), SBS's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: SBS's dividends in 3 years are forecast to be well covered by earnings (36% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Marcus Wolfinger (52yo)
Mr. Marcus Wolfinger has been Chairman of Management Board and Chief Executive Officer at STRATEC Biomedical AG since April 01, 2011 and its Member of the Management Board since July 1999. Mr. Wolfinger ha ...
CEO Compensation Analysis
Compensation vs Market: Marcus's total compensation ($USD1.15M) is about average for companies of similar size in the German market ($USD1.19M).
Compensation vs Earnings: Marcus's compensation has been consistent with company performance over the past year.
|Chairman of Board of Management & CEO||8.8yrs||€1.06m||no data|
|Director of Finance & Human Resources and Member of Board of Management||9yrs||€765.00k||no data|
|Director of Product Development & Member of Board of Management||6yrs||€669.00k||no data|
|Founder & Advisor||8.9yrs||no data||2.38% €19.6m|
|Head of Investor Relations||0yrs||no data||no data|
|Director of Corporate Communications||0yrs||no data||no data|
|Head of Supply Chain Management & Senior VP||0yrs||no data||no data|
Experienced Management: SBS's management team is seasoned and experienced (8.9 years average tenure).
|Chairman of the Supervisory Board||0.8yrs||no data||no data|
|Member of Supervisory Board||5.7yrs||€29.00k||no data|
|Deputy Chairman of Supervisory Board||2.7yrs||€41.00k||no data|
Experienced Board: SBS's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Stratec SE's company bio, employee growth, exchange listings and data sources
- Name: Stratec SE
- Ticker: SBS
- Exchange: XTRA
- Founded: 1979
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €824.936m
- Shares outstanding: 12.03m
- Website: https://www.stratec.com
Number of Employees
- Stratec SE
- Gewerbestrasse 35-37
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SBS||DB (Deutsche Boerse AG)||Yes||Registered Shares||DE||EUR||Oct 1998|
|SBS||SWX (SIX Swiss Exchange)||Yes||Registered Shares||CH||CHF||Oct 1998|
|SBS||XTRA (XETRA Trading Platform)||Yes||Registered Shares||DE||EUR||Oct 1998|
|0RAR||LSE (London Stock Exchange)||Yes||Registered Shares||GB||EUR||Oct 1998|
|SBSD||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Registered Shares||GB||EUR||Oct 1998|
|SBS||ETLX (Eurotlx)||Yes||Registered Shares||IT||EUR||Oct 1998|
STRATEC SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. The company operates in three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technology. STRATEC SE also develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to STRATEC SE in December 2018. STRATEC SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/21 23:12|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.